Sandoz Completes Acquisition of Generic Dermatology Company Fougera for $1.5 Billion - - BioPharm International

ADVERTISEMENT

Sandoz Completes Acquisition of Generic Dermatology Company Fougera for $1.5 Billion



Sandoz announced it has completed the acquisition of Fougera Pharmaceuticals, a maker of generic dermatology products, for $1.525 billion in an all-cash transaction.  According to a company press release, the acquisition will complement Sandoz’s existing pipeline of biosimilars and generic injectables, ophthalmics and antibiotics.  Sandoz plans to use its global reach to expand Fougera’s dermatology portfolio into new markets.

Currently, Fougera Pharmaceuticals employs approximately 700 people across its US sites. It operates two main businesses: Fougera, specializing in dermatology development and manufacturing, with expertise in the area of semi-solid forms such as creams and ointments, and PharmaDerm, a branded specialty pharma business. Fougera will be integrated into Sandoz’s US business based in Princeton, NJ, but will continue to exist as a separate legal entity. Fougera’s site in Melville, NY, will be home to a new center of excellence for generic dermatology development and manufacturing within the global Sandoz network.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines

Click here